Article
A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study.
ESMO open - 1 Feb 2026
Liu Q, Fan Y, Huang C, Wu M, Jin Y, Tao L, Liu Y, Song J, Wang S, Kong W, Huang X, Ha C, Cui Z, Zhao D, Yang X, Qiao J, Zhang Y, Li Y, Guo H
Abstract excerpt
BACKGROUND: Although poly (ADP-ribose) polymerase inhibitors (PARPis) have transformed the treatment landscape for the BReast CAncer susceptibility gene (BRCA)-mutated ovarian cancer, emerging evidence suggests significant heterogeneity in treatment efficacy. However, findings regarding the impact of mutation location and type remain debated, underscoring the necessity for more data and better subclassification....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.